Ultra-low Molecular Weight Heparin Market Trends, Size, Share, Growth and Forecast by 2028

Ultra-low Molecular Weight Heparin Market Size – USD 6.76 Billion in 2020, Market Growth – at a CAGR of 1.4%, Market Trends – Rising number of clinical trials to understand the efficacy of heparin as a therapy for COVID-19

The global Ultra-low Molecular Weight Heparin market size is expected to reach USD 7.55 Billion in 2028 at a CAGR of 1.4% during the forecast period, according to the latest report by Reports and Data. Rising demand for Ultra-low Molecular Weight Heparin due to high prevalence of chronic conditions such as last-stage renal disease, atrial fibrillation, and cardiovascular diseases, increasing number of surgical procedures performed across the globe, and extensive RD activities to explore other clinical and therapeutic roles of Ultra-low Molecular Weight Heparin are key factors expected to drive market revenue growth over the forecast period. In addition, Ultra-low Molecular Weight Heparin is used for various off-label indications in hospitals and for treatment and prevention of venous thromboembolism events in post-surgical patients, and this is another factor expected to contribute to revenue growth of the market going ahead.

Ultra-low Molecular Weight Heparin is a widely used anticoagulant that significantly reduces clotting risks and thromboembolism events after major surgical interventions. Ultra-low Molecular Weight Heparin is a naturally occurring polysaccharide belonging to the family of glycosaminoglycans that are primarily present in mast cell. Ultra-low Molecular Weight Heparin exerts anticoagulant properties by binding to antithrombin and enhancing the subsequent inhibitory effect of antithrombin on thrombin and activated factor X. The currently available Ultra-low Molecular Weight Heparin is mostly obtained from animal tissue. However, due to growing concerns regarding animal safety, several approaches for bioengineering Ultra-low Molecular Weight Heparin such as microbial production and chemoenzymatic modification among others are increasingly being researched on. Major players are also focusing on RD for its potential clinical and therapeutic applications such as anti-inflammatory and anti-tumor activities as well as role in prevention of infectious diseases, besides its use as an anticoagulant. Ultra-low Molecular Weight Heparin has antineoplastic properties along with anticoagulant properties, and this is expected to result in increasing research activities to explore potential of Ultra-low Molecular Weight Heparin for treating various other conditions. This, in turn, is expected to significantly contribute to market revenue growth going ahead.

Venous thromboembolism prophylaxis with anticoagulant therapy is often used for cancer patients who are hospitalized or undergoing chemotherapy. However, possible risks of bleeding with the use of Ultra-low Molecular Weight Heparin and its derivatives have limited its use in management of cancer patients in other therapeutic settings, and this could hamper market growth to a certain extent over the forecast period.

Some Key Highlights from the Report:

  • Low-molecular-weight Ultra-low Molecular Weight Heparin (LMWH) segment is expected to account for largest revenue share over the forecast period, attributable to increasing preference for LMWH over unfractionated Ultra-low Molecular Weight Heparin in clinical settings, in treatment of venous thromboembolism events, and in obstetrics due to low risk of bleeding and other complications associated with it.
  • Subcutaneous route of administration is expected to register significant revenue growth during the forecast period, owing to growing preference for subcutaneous therapy of Ultra-low Molecular Weight Heparin, lesser incidence of pain and higher patient comfort, and low risk of recurrent thromboembolism when treated with subcutaneous injection of low-molecular weight Ultra-low Molecular Weight Heparin.
  • Venous thromboembolism is expected to dominate other application segments between 2021 and 2028 owing to increasing incidence of VTE among post-operative patients and rising need for anticoagulant therapy with low-molecular weight Ultra-low Molecular Weight Heparin.
  • Hospital pharmacies segment is expected to register steady revenue CAGR over the forecast period, attributable to increasing hospital admission of patients needing surgeries or dialysis, availability of high-quality Ultra-low Molecular Weight Heparin derivatives, growing number of outpatient procedures, and increasing reliance on pharmacists and doctors.
  • North America is expected to account for a significantly large revenue share over the forecast period, attributable to rising incidence of cardiovascular diseases and chronic illnesses, rising number of surgical procedures performed, availability of high-end medical facilities and medications, and robust presence of key players in the market.

In-depth Study of the Competitive Landscape:

The global Ultra-low Molecular Weight Heparin market consists of various market players, which make this business sphere highly competitive. In this section of the report, the authors have provided authentic information on product portfolios, new product innovations, technological capabilities, and product pricing strategies of each of these players. Moreover, it discusses the key strategies implemented by these players, such as mergers acquisitions, joint ventures, collaborations, partnerships and agreements, to build on their market presence.

Top companies profiled in the report include:

Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sanofi SA, B. Braun Melsungen AG, GlaxoSmithKline PLC, LEO Pharma A/S, Aspen Holdings, Fresenius SE Co. KGaA, and Viatris Inc.

Key Market Regions Covered in the Report:

  • North America (U.S., Canada)
  • Europe (U.K., Italy, Germany, France, Rest of EU)
  • Latin America (Chile, Brazil, Argentina, Rest of Latin America)
  • Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
  • The Middle East Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Product Type Outlook (Revenue, USD Billion; 2018-2028)

  • Unfractionated Ultra-low Molecular Weight Heparin
  • Low Molecular Weight Ultra-low Molecular Weight Heparin
  • Ultra-low Molecular Weight Ultra-low Molecular Weight Heparin

Route of Administration (Revenue, USD Billion; 2018-2028)

  • Subcutaneous
  • Intravenous

Application Outlook (Revenue, USD Billion; 2018-2028)

  • Coronary Artery Disease
  • Venous Thromboembolism
  • Atrial Fibrillation
  • Renal Impairment
  • Others

Distribution Channel Outlook (Revenue, USD Billion; 2018-2028)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently asked questions addressed in the report:

  • What is the revenue growth rate of the global Ultra-low Molecular Weight Heparin market over the forecast period?
  • What are the major factors driving the growth of the Global Ultra-low Molecular Weight Heparin Market?
  • What are the key challenges impacting the global Ultra-low Molecular Weight Heparin market growth?
  • What are the outcomes of the SWOT Analysis and Porter’s Five Forces Analysis conducted in the report?

Request for a Sample report of Ultra-low Molecular Weight Heparin Market @ https://www.reportsanddata.com/sample-enquiry-form/4154 

Thank you for reading our report. Do connect with us in case of any more queries about the report and its customization. Our team will ensure the report is well suited to cater to your needs.

Browse More Reports:

Antiviral Drugs Market @ https://www.reportsanddata.com/report-detail/antiviral-drugs-market

Coronary Stents Market @ https://www.reportsanddata.com/report-detail/coronary-stents-market

Live Cell Imaging Market @ https://www.reportsanddata.com/report-detail/live-cell-imaging-market

Defibrillator Market @ https://www.reportsanddata.com/report-detail/defibrillator-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.


David Jone

53 Blog posts

Comments